| 1 |
35603651 | [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways]. | 2022 May |
3 |
| 2 |
32470534 | Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. | 2020 Oct 1 |
1 |
| 3 |
30959969 | Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling. | 2019 Apr 7 |
1 |
| 4 |
28427224 | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. | 2017 May 9 |
1 |
| 5 |
28500237 | Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. | 2017 Aug |
1 |
| 6 |
27783942 | Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. | 2016 Oct 25 |
1 |
| 7 |
22409268 | Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. | 2012 May |
1 |